Product Description
CellMosaic® has designed this kit to label any antibody (IgG) with high amount of Deruxtecan.
| Download Documents | |
| SDS | USER MANUAL |
Trastuzumab Deruxtecan, sold under the brand name Enhertu, typically has an average of 8 molecules of Deruxtecan attached to each antibody molecule (Nakada, T. et al. Bioorg. Med. Chem. Lett. 2016, 26, 1542−1545). This kit is designed for loading approximately 8 Deruxtecan molecules per antibody. It is only recommended for use after performing conjugation with CM11431 (targeting 4 Deruxtecan per antibody) and confirming that significant aggregations or precipitations was not observed with your antibody using that kit.
The kit provides the materials to conjugate 1 to 3 mg of one antibody sample (CM11434x1) or three antibody samples (CM11434x3) of IgG with Deruxtecan, using enzymatic cleavable peptide linker, GGFG.
Drug Information
- Name: Deruxtecan (Mc-GGFG-DXd)
- Synonym: Exatecan derivative, DX 8951 derivative; DXd; payload for DS-8201a
- CAS number: 1599440-13-7
- Chemical formula: C52H56FN9O13
- MW: 1034.0684
- Mechanism of action: Trastuzumab Deruxtecan, sold under the brand name Enhertu was approved by US FDA for treating metastatic HER2-postive breast cancer.
Requirement for Antibody
- Preferably >90% pure by gel electrophoresis
- Total amount: 1-3 mg of protein content as measured by UV.
Key Features of this PerKit™
- Simple and efficient labeling of IgG with Deruxtecan, minimizing toxin exposure.
- Features enzymatic cleavable GGFG peptide linker.
- Delivers an average of 8 Deruxtecan molecules per antibody.
- Fast preparation: 4 hours total, with less than 1 hour of hands-on time.
- Includes all necessary reagents and supplies for preparation and purification.
- Achieves over 95% conjugation, free from unreacted drugs.
- Post-conjugation services are available from CellMosaic for analysis and DAR determination.
Conjugation Chemistry
Protocol
Schematic workflow diagram for preparing antibody-Deruxtecan conjugates, starting with 3 mg of IgG. (Reagent volumes will vary if the amount of IgG is less than 3 mg.)
Related Products
ADC Control hIgG1-Deruxtecan (Product #: CM51103): A control ADC made with a non-binding human IgG1 subtype. This product contains an average of 4 deruxtecan molecules per antibody and has low endotoxin levels, making it suitable for in vitro and in vivo studies.
ADC Control Kit with VC-PAB Linker (Product #: CM11429): A negative control ADC preparation kit utilizing the VC-PAB linker.
Hydrophobic Interaction Chromatography (HIC) Buffer Set (Product#: CM02025): Designed for ADCs prepared via reduced thiols of the antibody, HIC HPLC is used to calculate the Drug-to-Antibody (DAR) and assess ADC heterogeneity. Conjugates are separated based on hydrophobicity, and antibodies with the same DAR will elute as a single peak. For typical MMAE ADCs, multiple peaks represent varying drug loads. The HIC Buffer set is accompanied by a product sheet with all of the information and methodology needed for HIC HPLC analysis. If you lack HPLC access, CellMosaic® offers sample analysis services.
Size Exclusion Chromatography (SEC) HPLC Protein Standards (Product #: CM92004 and CM92005): SEC HPLC separates the conjugates by apparent molecular weight (MW) or size in an aqueous solution. Larger MW conjugates elute earlier. Comparing SEC profiles of unlabeled IgG and ADCs allows you to estimate aggregation levels. CellMosaic® provides two SEC standards for use with any SEC column. The product sheet includes detalied methodology for running SEC HPLC analysis. If you lack HPLC access, CellMosaic® can perform the analysis for you.
ADC stabilizing PBS buffer (5x) (Product #: CM02022): This buffer contains 5x PBS and other stabilizers to prevent hydrophobic drug interactions during storage, which can cause ADC precipitation. It also preserves ADC structure lyophilization. The buffer is biocompatible and suitable for in vitro and in vivo studies.
